AdAlta To Raise Funds To Take Shark-Derived Fibrosis Candidate Into Clinic
Executive Summary
Australian biotech company AdAlta develops protein therapeutics based on shark antibodies, much the same way as Ablynx and others use camelid antibodies. It has just applied to raise an IPO on the Australian Securities Exchange [ASX] to fund clinical studies with its lead compound AD-114 which shows promise in treating fibrosis.